The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Oliva, F. G., Orso, F., Basile, C., Colivicchi, F., Cipriani, M., Lenarda, A. D., Gori, M., Gorini, M., Iacoviello, M., Gonzini, L., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106860
Hiura, K., Masuda, H., Sakunami, M., & Yamashita, M. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70335
Xue, X., Hu, M., Chi, J., Li, J., & Zhang, W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1816804
Beyond glycemic control: rethinking the diabetic heart
Rossi, V. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03204-1
Yoon, M., & Park, J. J. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0111
Crisóstomo, V., Báez-Díaz, C., Sánchez‐Peralta, L. F., Vázquez-López, F., Torrescusa, A., Gálvez‐Montón, C., & Sanchez-Margallo, F. M. (2026) · European journal of medical research · doi:10.1186/s40001-026-04557-9
Ambalavanan, J., Bhasin, K., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.013
Titin Modification as a Potential Treatment for Chronic Heart Failure with Preserved Eject Fraction
Vakhrushev, Y. A., Bagandov, A. A., Lyasnikova, E. A., & Kostareva, A. A. (2026) · Translational Medicine · doi:10.18705/2311-4495-2026-13-31-41
Umanath, K., Dwyer, J. P., & Mentz, R. J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1845339
Yin, M., Tan, H., Xie, S., Kuang, Y., Wu, Q., Ma, J., & Guo, C. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1799557
Alfie, T., Wasfy, J. H., Kazi, D. S., Januzzi, J. L., Bellows, B. K., & COHEN, L. P. (2026) · Circulation Population Health and Outcomes · doi:10.1161/circoutcomes.125.012989
Fudim, M., Ferrante, F., Vorgang, C. M., Rosner, C. M., & Mentz, R. J. (2026) · Future Cardiology · doi:10.1080/14796678.2026.2683489
Shi, M., Li, Y., Zhu, Z., Xie, Y., & Zhang, X. (2026) · Antioxidants · doi:10.3390/antiox15060716
Su, Q., Huang, W., Hu, C., Huang, Y., Mo, L.-E., Wu, Q., & Huang, Y. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048427
Prosperi, S., Monosilio, S., D’Amato, A., Angotti, D., Filomena, D., Netti, L., Tonti, G., Pedrizzetti, G., Cimino, S., Badagliacca, R., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13060260
Belanger, N., Zeid, S., Gieswinkel, A., Kazemi-Asrar, F., Velmeden, D., Rausch, F., Dinh, W., Lackner, K. J., Gori, T., Lurz, P. C., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag139
Adnan, Y., Thirupathy, U., Abouayana, A., Elsammani, A., Deiab, A. T., Abdelrahman, M. A. G., Hussein, M. J. A.-A., Ali, M. U., Nawaz, M., Basu, S., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001367
Finerenone after FINEARTS-HF: evidence boundaries and implementation in heart failure with LVEF ≥40%
Feng, S., & Jin, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1880045
SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms
Ryabenko, K., Schini‐Kerth, V. B., Ohlmann, P., & Galli, E. (2026) · Biomolecules · doi:10.3390/biom16060873
彭卫华, Shang, X., Zhang, C., & Liu, M. H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1849205 · Cited by 1
Targeting inflammatory pathways in T2DM: Therapeutic interventions
Ali, S., & Jamous, Y. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33590-7.00003-4
Cardiac immunity and heart repair: Mechanism, challenge, and future direction
Liu, Y., Ren, Q., Wang, H. T., Jiang, X., Zhao, M. H., Min, Q., Xie, Y., Cai, D., & Nie, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004078
Stratégies thérapeutiques dans le traitement du diabète de type 2
Bordier, L., & Bauduceau, B. (2026) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(25)49531-6
Les traitements du diabète de type 2 : les preuves
Bordier, L., & Bauduceau, B. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100822
Mavraganis, G., Fragoulis, C., Georgiopoulos, G. A., Mavromoustakou, K., Dimitriadis, K. P., Aznaouridis, K. A., Chrysohoou, C. A., Stamatelopoulos, K. S., & Tsioufis, K. P. (2026) · Medicina · doi:10.3390/medicina62071222
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2026.0018
SLCs in diabetic kidney disease: From pathogenic roles to therapeutic promises
Zhang, Y., Zheng, D., Han, R., Liu, J., Wang, X., & Fu, S. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124558
Mohanty, S. S., Selvammathy, R. R., Ahad, H. A., & Kumar, E. S. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_1384_25
Wu, J., Cai, Y., Chen, J., Zang, Q., Zhu, P., & Ding, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1860779
From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease
Maggioni, A. P., Orso, F., Lucci, D., Luca, L. D., & Colivicchi, F. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134646
Png, M. E., Tahsina, T., Jones, N. R., Taylor, C. J., Petrou, S., & Hobbs, R. F. (2026) · Heart · doi:10.1136/heartjnl-2026-328059
Northway, J., Park, J., Mankowitz, K., & Hoque, F. (2026) · Journal of Brown Hospital Medicine · doi:10.56305/001c.163599
Davutoğlu, Y., Akarsu, H., Sevgican, C. İ., Kayhan, Ö. Ö., Aybek, H., Kilic, D., Tekin, I., & Büber, İ. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00746-4
Müller, L.-M., Krampe, J., Katzmann, J. L., Laufs, U., & Kögel, A. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02962-y
Lin, J., Zhou, C., Ding, J., Brieger, D. B., Rhee, J., Yu, J., Ye, Z., Guo, J., Xie, Z., Qin, X., et al. (2026) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvag158
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8847
Tang, T., Yu, H., Zhang, Y., Li, S., & Guo, M. (2026) · Cardiology Research and Practice · doi:10.1155/crp/1274068
Ferreira, V. M., & Muller, V. A. (2026) · Cureus · doi:10.7759/cureus.113025
Giannino, F., Colarusso, L., Mancuso, M., Piccione, M. C., Bella, G. D., Micari, A., & Zito, C. (2026) · Journal of Cardiovascular Echography · doi:10.4103/jcecho.jcecho_11_26
Arabacı, H. O., Ozkan, F., Güven, Z., Geçit, M. H., Arslan, Ş., & Arslan, Ş. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145681
Alhowail, A. H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1895764
Insufficienza cardiaca: gestione perioperatoria
Jendoubi, A., Damy, T., & Mongardon, N. (2026) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(26)51981-9 · Cited by 1
Meta-Analysis of SGLT2 Inhibitors in Transthyretin Cardiac Amyloidosis
Bianchi, L., Marchionni, G., Chendey, T., Benenati, S., Minghini, A., Giannino, F., Cavolina, G., Soragni, C., & Chimenti, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102972
Palomo‐Piñón, S., Alcocer, L., Álvarez‐López, H., Enciso‐Muñoz, J. M., Galván‐Oseguera, H., Chávez‐Mendoza, A., Díaz‐Díaz, E., Muñoz, E. G. C., & Rosas-Peralta, M. (2026) · Annals of Clinical Hypertension · doi:10.29328/journal.ach.1001044
Guo, Y., Zhang, Y., Liu, S., & Zou, D. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00317-0
Dakhil, Z. A. (2026) · Cardiovascular Medicine · doi:10.3390/cardiovascmed29030029
Felici, A. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113473
Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies
Zhang, S., Xu, C., Song, Y., & Zhang, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156881
Gill, A., Li, T., Jimenez, S., Cadeiras, M., Fan, D., Singh, S., & Ebong, I. (2026) · Heart · doi:10.1136/heartjnl-2026-328221
Impact of Empagliflozin on Serum Calcium and Phosphate in Heart Failure
Ferreira, J. P., Zannad, F. M., Filippatos, G. S., Marques, P. S., Vasques‐Nóvoa, F., Neves, J. S., MENDONÇA, L., Butler, J., Anker, S. D., & Packer, M. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.07.026
Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction
Beavers, C. J., & Greene, S. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10656-w
Wang, D., Cai, W., Wang, R., Luo, W., Liu, Y., Zhou, Q., & Jiang, Y. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261479258
de Alencar, M. L., Morais, M. C., de Almeida, J. B., & Reis, P. H. D. C. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i3.584
Yang, Z., Zhao, Z., Jiang, C., Xu, Y., Xu, H., Guo, H., Wang, Y., Li, M., Zhou, L., He, L., et al. (2026) · Cardiology Discovery · doi:10.1097/cd9.0000000000000204
Huang, T., Yap, L., Lin, H., Su, P., Liao, Y., Chen, C., Lee, P., Lin, S., & Li, Y. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049649
Chabalout, M. N., Alazzeh, M., Othman, D., & Virk, J. P. S. (2026) · Cureus · doi:10.7759/cureus.115294
Seth, S., Chopra, V., Sinha, N., Nair, T., Böhm, M., Sawhney, J. P. S., Oomman, A., Jaswal, A., Gopi, A., Rao, S., et al. (2026) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_64_26
Mortality Still Matters in Clinical Trials for Heart Failure
Neto, J. M. R. (2026) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20260018i
Raposeiras‐Roubín, S., Gonzalez-Manzanares, R., Amat-Santos, I. J., Melendo‐Viu, M., Dobarro, D., López‐Otero, D., Franco, L. N., Gheorge, L., y, J. S.-S., Carlos, B. Z., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag242
A Mortalidade Ainda Importa nos Estudos Clínicos em Insuficiência Cardíaca
Neto, J. M. R. (2026) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20260018
Promoting Healthy Aging with Gerotherapeutic Medications
Kwon, O. S., & Al‐Naggar, I. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-21928-2_24
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.95.108
Immunometabolic regulation of cardiac macrophages in heart failure with preserved ejection fraction
Liang, J., Su, M., Liu, R., Li, T., Qin, Z., & Wáng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896936
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
Guerra, G., Niro, F., Mergiotti, M., Gavatorta, G., Hirsch, E., & Ghigo, A. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70666
Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin
Habeos, E. E., Markantes, G. Κ., Parthymou, A., Dimitropoulos, K., Habeos, G. I., Papasotiriou, M., Marangos, M. N., & Chartoumpekis, D. V. (2026) · Biomedicines · doi:10.3390/biomedicines14092016
Beyond glycemia: What SGLT2 inhibitors in non-diabetic heart failure really teach us
Fonseca, C., & Brito, D. A. (2026) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2026.08.003
Type 2 Diabetes: Chronic Clinical Metabolic Effects of SGLT2 Inhibitors
Scheen, A. J. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_848
Li, Z., Surapaneni, A., Charytan, D. M., Horwitz, L. I., Blecker, S., Shin, J., Thorpe, L. E., Melamed, M. L., & Grams, M. E. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001252
Simon, A., Prakash, S., & Samuel, J. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02669-1
Ji, K., Zhang, D., Zhao, Y., Zeng, Z., Jiang, M., & Zhang, J. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101793
Atajanova, J., Rafiq, S., & Cao, G. (2026) · Romanian Journal of Cardiology · doi:10.2478/rjc-2026-0025
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Ma, Q., Zhang, S., Guan, C., Liu, Y., Yang, X., Chen, X., Jin, S., & Xiao, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838338
Ausiello, A., Lalaguna, L., López-Olañeta, M. M., Torroja, C., Palacios-Merino, J., Sánchez‐Cabezudo, C., Rivas, P., Villalba‐Orero, M., Fernandez-Cortes, E., García‐Pavía, P., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag193 · Cited by 1
Cozma, D. C., Tudoran, C., & Văcărescu, C. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101008
Aldossary, L. A., Alanazi, R. M., Almutairi, R. M., Mugibel, T. A., Ghanam, K. D., Ben-obaidellah, R. A. R., Mohammed, K. A., Alharbi, A. A., Almahabi, J. A., Alzahrani, R. A. S., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001483
SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications
Zheng, X.-T., Xie, H.-Y., Wang, X.-H., Zhao, Y., Yang, J.-Y., Liu, Y.-X., Yuan, X.-L., Tang, H.-F., Jiang, Z., & Hu, H.-J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00604-3
Wang, H., Li, Y., Qin, C., Chen, X., Wang, K., Zhang, M., & Cheng, W. (2026) · iScience · doi:10.1016/j.isci.2026.117553
Villarroel-Casco, J. R., Ramírez-Carvajal, J. V., Reisancho-Tenelema, J. A., & Encalada-Bermeo, E. A. (2026) · Sanitas. Revista arbitrada de ciencias de la salud. · doi:10.62574/nqfbwm39
Packer, M., Butler, J., Zannad, F., Vaduganathan, M., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.09.029
Self-citationBoettger, P., Nakou, E. S., Kinsley, T., Buerke, M., Wild, E., & Sossalla, S. T. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00830-0
Mohamed, A. A., Husain, B. H., Dali, T. K., Ahmed, M. E., Shawawreh, G. A., Samir, A., Moussa, M. A., Hibysh, A. M., Shehata, A. G. S. F., Ramadan, Y., et al. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8933859
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Simões, M. V., Moura, L. Z., Martins, S. M., Mourilhe‐Rocha, R., Danzmann, L. C., Neto, J. A. D. F., Marcondes‐Braga, F. G., de Oliveira, M. T., de Albuquerque, D. C., Freitas, A. F., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260830
Bunnel, K. T., Baldoni, A. O., & Reges, R. B. E. (2026) · Research Square · doi:10.21203/rs.3.rs-11090217/v1
Eisa, N., & Khoury, M. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02097-x
Beyond Cardiorenal Risk Factors: The Prognostic Role of Frailty in Acute Heart Failure
Aletras, G., Marketou, M. E., Bachlitzanaki, M., Stratinaki, M., Tsigaridaki, M., Pantazis, Y., Foukarakis, E. G., Hamilos, M., & Stylianou, K. (2026) · Medicina · doi:10.3390/medicina62101942
Tang, X., Niu, W., Lan, Z., & Zhong, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1969057
Therapie des Typ-2-Diabetes – Praxisempfehlung der DDG
Gallwitz, B., Aberle, J., Birkenfeld, A. L., Kellerer, M., Klein, H. H., Landgraf, R., Müller‐Wieland, D., Müssig, K., Nauck, M., Siegel, E. G., et al. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2866-0999
Suzuki, Y., Onishi, T., Nakano, Y., Shimoda, M., Goto, R., Suzuki, T., & Amano, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208158
Demidova, T. Y., & Izmaylova, M. Y. (2026) · National Health Care (Russia) · doi:10.47093/2713-069x.2026.7.2.18-26
Insuficiencia cardíaca: manejo perioperatorio
Jendoubi, A., Damy, T., & Mongardon, N. (2026) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(26)52197-2
Trimetazidine in Heart Failure: From Metabolic Modulation to Clinical Outcomes—A Narrative Review
Pradhan, A. K., Prajapathi, S., Mahajan, K., Batta, A., & Perrone, M. A. (2026) · Pharmaceuticals · doi:10.3390/ph19101663
Kajo, C., AlAraibi, A. J., Almutairi, O. T., Alaraibi, Y. H., Alibrahim, A. A., Almutawah, Y. K. A., Alasfar, S. W. S., Ali, M. W., Hajjiri, A., Alqaryuti, M., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1976876
Nzobokela, J., Choolwe, S. C., & Masenga, S. K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1987811
Moady, G., Maman, S., Dragu, R., Levi-Gofman, L., & Atar, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1975531
Wang, S., Nolte, I. M., Groothof, D., Qin, H., Bakker, S. J. L., van der Harst, P., & Snieder, H. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag539
Banga, A., & DEEDWANIA, P. C. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.10.018
Guzmán-Carreras, A., Bernabeu‐Wittel, M., Hoyo, R. S.-D., Muñoz‐Rivas, N., Sánchez-Sauce, B., Aguilar-Rodríguez, F., Cabeza-Osorio, L., Andrès, E., Lorenzo-Villalba, N., & Méndez‐Bailón, M. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107667
Inibidores do SGLT2: Gestão de Eventos Adversos na Prática Clínica
Ramalho, C., Ferreira, J. P., Neto, N. J., & Marques, P. S. (2026) · Acta Médica Portuguesa · doi:10.20344/amp.24617
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
